

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **May 31, 2019**

**BRAIN SCIENTIFIC INC.**

(Exact Name of Registrant as Specified in Charter)

Nevada  
(State or Other Jurisdiction  
of Incorporation)

333-209325  
(Commission  
File Number)

81-0876714  
(I.R.S. Employer  
Identification No.)

**205 East 42<sup>nd</sup> Street, 14<sup>th</sup> Floor**  
**New York, New York 10017**  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(646) 388-3788**

\_\_\_\_\_  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).  
Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Not applicable	Not applicable	Not applicable

**Item 5.02****Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 31, 2019, Jesse W. Crowne resigned as Chief Executive Officer of Brain Scientific Inc. (the "Company"). Mr. Crowne will remain with the Company as a director and will serve, subject to his prior resignation or removal, in accordance with the By-Laws of the Company and until his successor is duly elected and qualified.

As a result of Mr. Crowne's resignation, the Company's Board of Directors unanimously decided that it will collectively manage the Company until such time as a new CEO is identified and appointed.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 6, 2019

**BRAIN SCIENTIFIC INC.**

By: /s/ Boris Goldstein  
Name: Boris Goldstein  
Title: Chairman of the Board and Secretary